Dr. Reddy’s Laboratories (DRL) together with its subsidiaries introduced the launch of Ertapenem for Injection, a therapeutic equal generic model of INVANZ.
INVANZ is a trademark of Merck and Co., Inc. The INVANZ model and generic market had U.S. gross sales of roughly $205 million MAT for the latest twelve months ending in March 2021 based on IQVIA Well being.
Dr. Reddy’s Ertapenem for Injection, 1 g/vial, is accessible in packs of 10 vials per carton.
Dr. Reddy’s Laboratories together with its subsidiaries introduced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equal generic model of INVANZ (ertapenem for injection) for injection, 1 g/vial authorized by the U.S. Meals and Drug Administration (USFDA).
Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories mentioned, “We’re excited to increase our strategic partnership with Gland Pharma whose arduous work, in collaboration with the crew at Dr. Reddy’s, has enabled the execution of this launch.
Srinivas Sadu, MD and CEO of Gland Pharma mentioned, “We’re delighted about this collaboration, because it brings collectively Dr. Reddy’s skilled advertising and distribution capabilities and Gland Pharma’s strong improvement and manufacturing capabilities. Gland Pharma has an unique API provide association for this product and a devoted manufacturing facility in Hyderabad for Ertapenem Injection. With the launch of this product we see elevated capability utilization of this devoted Penem facility.
The announcement was made earlier than market hours as we speak, 12 Could 2021. Shares of Dr Reddy’s Laboratories fell 0.67% to settle at Rs 5,293.60 yesterday, 11 Could 2021.
Dr Reddy’s Laboratories is an built-in pharmaceutical firm. By way of its three companies – pharmaceutical providers & lively elements, international generics and proprietary Merchandise.
Powered by Capital Market – Stay Information
(This story has not been edited by Enterprise Commonplace workers and is auto-generated from a syndicated feed.)